The Jasper Therapeutics Inc (NASDAQ: JSPR) stock price soared 400% after releasing positive data from a phase I/II clinical trial evaluating the addition of Briquilimab to an existing bone marrow transplantation regimen in patients suffering from sickle cell disease (SCD) and beta-thalassemia.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
The data from the first three participants was celebrated by investors, given that Briquilimab is being studied as a potential way to achieve a higher percentage of healthy donor stem cell engraftment (donor chimerism) without increased toxicity.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- IG Top-tier regulation – Read our Review
- XTB UK regulated by the FCA – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Investors cheered the positive initial results, given that the target patients were at high risk for complications from or ineligible for standard myeloablative hematopoietic stem cell transplant. The study was led by Dr John F. Tisdale, Director of the Cellular and Molecular Therapeutics Laboratory, NHLBI.
Ronald Martell, Jasper Therapeutics President and CEO, said: “While stem cell infusion with healthy donor stem cells or gene-corrected cells are potentially curative options for SCD and beta-thalassemia, they are both limited by the toxicity of current conditioning regimens using busulfan or melphalan, which are often cited as the most concerning safety risks for transplant patients and physicians.”
The transplantation of healthy donor stem cells to SCD and beta-thalassemia patients in a multi-stage process. First, the donor cells are collected, after which the recipient's stem cells are cleared from the bone marrow to create room for the transplanted cell. This process is known as bone marrow conditioning.
After the conditioning, the healthy stem cells are introduced into the recipient’s bone marrow, after which they must survive. This process is referred to as bone marrow engraftment. Finally, the proportion of the donor cells to the recipient’s cells is measured to determine the success of the engraftment process. This is known as donor chimerism.
Improving donor chimerism in patients who have undergone stem cell transplants is crucial to ensuring that a sufficient amount of healthy donor stem cells is available to produce healthy red blood cells and reverse the sickle phenotype after the transplant.
The clinical trial’s primary endpoint was to determine if adding briquilimab would increase the proportion of patients with donor myeloid chimerism ≥98% at 1-year post-transplant. The study is currently enrolling additional patients.
*This is not investment advice.
Jasper Therapeutics (JSPR) stock price.
The Jasper Therapeutics (JSPR) stock price rallied 400% to trade at $2.40, rising from Friday’s closing price of $0.48.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
